...
首页> 外文期刊>International journal of colorectal disease. >ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.
【24h】

ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.

机译:ABCB1 / MDR1基因多态性作为结直肠癌的预后因素。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: To analyse the single-nucleotide polymorphisms (SNPs): ABCB1(1236C>T), ABCB1(2677G>T/A), ABCB1(3435C>T) and haplotypes in the ABCB1/MDR1 gene, which could contribute to genetic risk of colorectal cancer (CRC). Disease association between the ABCB1/MDR1 genotype, allele, haplotype frequencies and histological features, such as TNM classification, localization of primary carcinoma, grade of malignancy, histological type of tumour, lymphoid infiltration and vessel invasion were estimated. In this study, the potential role of SNPs of the ABCB1/MDR1 gene as a prognostic marker for CRC was analysed. MATERIALS AND METHODS: Tumour specimens of 95 patients with CRC were studied. Using automated sequencing or PCR-RFLP method, DNA for three common SNPs of ABCB1/MDR1 was extracted and analysed. The results of genotyping and haplotype analysis with histopathological features, grading and clinical staging of neoplasms were correlated. RESULTS: A statistically significant higher frequency of T(1236) allele in T1/T2 (89.7%), M0 groups (81.6%) and I/II clinical staging (82.7%) in comparison with T3/T4 (68.2%), M1 groups (47.4%) and III/IV clinical staging (65.1%) was detected. Furthermore, multivariate analysis according to Cox's proportional hazard model indicated that the T(1236) allele is a good, independent prognostic factor and the presence of this allele decreases the risk of death in comparison with a group without this allele (HR = 0.26; p = 0.0424). In addition, a statistically significant higher frequency of C(3435) allele and significant differences in the C(3435) allele distribution in N1/N2 group (91.7% and 62.5%, respectively) than N0 group (71.2% and 44.9%, respectively) was found. Each of the eight possible haplotypes was noted in M0 or I/II group and only seven in M1 or III/IV group. Haplotype T(1236)-G(2677)-C(3435) only in less advanced CRC subjects (9.6% in I/II and 9.2% in M0 group) was detected. In addition, significant differences in haplotype distributions between M0 or I/II and M1 or III/IV group were found (p = 0.01 and p = 0.05, respectively). CONCLUSIONS: These results suggest association between T(1236) allele and T(1236)-G(2677)-C(3435) haplotype and less advanced CRC, so these genetic markers may play a role as potentially good prognostic factors. Differences in haplotype distributions and degree of clinical staging may suggest that some other potential SNPs, especially in regulatory region of ABCB1/MDR1 gene, may influence P-glycoprotein function and CRC progression.
机译:目的:分析单核苷酸多态性(ANPB1(1236C> T),ABCB1(2677G> T / A),ABCB1(3435C> T)和ABCB1 / MDR1基因的单倍型,这可能会导致遗传风险大肠癌(CRC)。估计了ABCB1 / MDR1基因型,等位基因,单倍型频率和组织学特征(例如TNM分类,原发癌的定位,恶性程度,肿瘤的组织学类型,淋巴样浸润和血管浸润)之间的疾病关联。在这项研究中,分析了ABCB1 / MDR1基因的SNPs作为CRC预后标志物的潜在作用。材料与方法:研究了95例CRC患者的肿瘤标本。使用自动测序或PCR-RFLP方法,提取和分析ABCB1 / MDR1的三个常见SNP的DNA。基因分型和单倍型分析结果与组织病理学特征,肿瘤分级和临床分期相关。结果:与T3 / T4(68.2%),M1相比,T1 / T2(89.7%),M0组(81.6%)和I / II临床分期(82.7%)的T(1236)等位基因发生率具有统计学显着性组(47.4%)和III / IV期临床分期(65.1%)。此外,根据Cox比例风险模型进行的多变量分析表明,T(1236)等位基因是一个良好的独立预后因素,与没有该等位基因的组相比,该等位基因的存在降低了死亡风险(HR = 0.26; p = 0.0424)。此外,与N0组(分别为71.2%和44.9%)相比,N1 / N2组(分别为91.7%和62.5%)的C(3435)等位基因在统计学上显着更高的频率和C(3435)等位基因分布的显着差异。 ) 被找到。在M0或I / II组中记录了8种可能的单倍型,而在M1或III / IV组中仅记录了7种。仅在较不高级的CRC受试者(I / II中为9.6%,M0组为9.2%)中检测到单倍型T(1236)-G(2677)-C(3435)。此外,在M0或I / II与M1或III / IV组之间的单倍型分布存在显着差异(分别为p = 0.01和p = 0.05)。结论:这些结果表明T(1236)等位基因和T(1236)-G(2677)-C(3435)单倍型和较不先进的CRC之间的关联,因此这些遗传标记可能作为潜在的良好预后因素。单倍型分布和临床分期程度的差异可能表明,其他一些潜在的SNP,特别是在ABCB1 / MDR1基因的调控区域,可能会影响P-糖蛋白功能和CRC进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号